Stereotaxis Announces European Adoption Milestone and Health Canada

Market Clearance for VdriveT System

ST. LOUIS, Feb. 8, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:

STXS) today announced that its VdriveT Robotic Navigation System,

which provides physicians the ability to remotely manipulate

traditionally non-robotic catheters, is growing in popularity and is

expected to surpass 500 clinical procedures in Europe in February.

The company also announced it has received regulatory clearance from

Health Canada to commercially market the device in Canada.

Since the initial product release in Europe in 2011, the Vdrive system

has been installed in nine centers, with units scheduled to be

installed in additional centers during the first quarter of 2012. The

initial nine centers have performed 473 clinical cases with

approximately 80% being completed in the left atrium of the heart.

Numerous cases have been performed with the VdriveT system and

clinical feedback continues to be very positive," said Michael P.

Kaminski, President and CEO of Stereotaxis. "With the Health Canada

market clearance for the Vdrive system, and our planned new Vdrive

installations in Europe and Canada this year, we are well-positioned

to drive the growth and further adoption of this exciting technology

in electrophysiology labs in these important markets."

In a fully remote procedure environment, the Vdrive system increases

the clinical techniques available to the physician and reduces the

need to re-enter the sterile field to adjust devices. Initial

clinical data from European physicians demonstrates that this

simplification saves 30 minutes(1) or more in robotic procedures,

depending on the individual clinical technique. Furthermore, the

addition of robotic diagnostic catheter manipulation is another step

in Stereotaxis' vision to improve device control. Stereotaxis' broad

EpochT solutions portfolio also includes precise magnetic control of

ablation catheters with Niobe@ ES and integrated display and control

of multiple lab technologies with the OdysseyT Clinical Information

Management System.

The design of the Vdrive system allows the robotic hardware to adapt

to different clinical techniques depending on the disposable adaptor

that is attached to the arm:

-- V-LoopT circular catheter manipulator allows control of circular

diagnostic catheters, primarily in left atrial procedures.

-- V-CAST catheter advancement system allows advancement and

retraction of the magnetic catheter as well as robotic manipulation of

catheter introducer sheaths that are already in use during the


-- V-CAS DeflectT catheter advancement system is a more advanced

device that includes an integrated robotic deflectable sheath.

Initial positive results from multiple physician users confirmed the

significant clinical value delivered by the Vdrive system related to

procedure efficiency.

-- Dr. Georg Noelker of the Herz- und Diabeteszentrum NRW in Bad

Oeynhausen, Germany commented on the V-Loop system: "We have adopted

Vdrive for navigating the circular mapping catheter for all of our

left atrial procedures. Our initial experience with Vdrive has shown

that we can reduce our left atrial procedures times by approximately

30%, and can further reduce our fluoroscopy times by an additional 14%

over our previous times with magnetic navigation alone."

-- Dr. Xu Chen of the Rigshospitalet in Copenhagen commented on the

V-CAS system: "The addition of robotic sheath control to a magnetic

procedure allows me to efficiently access even challenging areas of

the heart chambers and focus on patient therapy instead of catheter

control. The Vdrive control was intuitive and did not take long to

implement as a part of my procedure. In difficult cases the Vdrive

control even reduced my total procedure time."

-- Dr. Petr Neuzil of Homolce Hospital in Prague shared his

perspective on the V-CAS Deflect system: "The advancements in the

Vdrive technology use the best of previous magnetic and robotic

systems to provide a new level of catheter control, which is expected

to improve outcomes in ablation procedures."

The regulatory milestone in Canada covers both the V-Loop circular

catheter manipulator and the V-CAS catheter advancement system with

sheath manipulator. The Company's 510(k) submission for the V-Loop

circular catheter manipulator is under review by the U.S. Food and

Drug Administration.

(1) Stereotaxis data on file

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology

instrument control system for use in a hospital's interventional

surgical suite to enhance the treatment of coronary artery disease and

arrhythmias. The Niobe@ Remote Magnetic Navigation System is designed

to enable physicians to complete more complex interventional

procedures by providing image guided delivery of catheters and

guidewires through the blood vessels and chambers of the heart to

treatment sites. This is achieved using computer-controlled,

externally applied magnetic fields that govern the motion of the

working tip of the catheter or guidewire, resulting in improved

navigation and reduced x-ray exposure.

Stereotaxis' OdysseyT portfolio of products provides an innovative

enterprise solution for integrating, recording and networking

interventional lab information within hospitals and around the world.

OdysseyT Vision integrates data for magnetic and standard

interventional labs, enhancing the physician workflow through a

consolidated display of multiple systems and eliminating the challenge

of interacting simultaneously with many separate diagnostic systems.

The Odyssey CinemaT Studio then captures a complete record of

synchronized procedure data that can be viewed live or from a

comprehensive archive of cases performed. OdysseyT solution then

enables hospitals to efficiently share live and recorded clinical data

anywhere around the world to attract patients and promote


The core components of the Stereotaxis systems have received

regulatory clearance in the U.S., Europe, Canada and elsewhere. For

more information, please visit and

This press release includes statements that may constitute

"forward-looking" statements, usually containing the words "believe,"

"estimate," "project," "expect" or similar expressions.

Forward-looking statements inherently involve risks and uncertainties

that could cause actual results to differ materially from the

forward-looking statements. Factors that would cause or contribute to

such differences include, but are not limited to, continued acceptance

of the Company's products in the marketplace, the effect of global

economic conditions on the ability and willingness of customers to

purchase our systems and the timing of such purchases, our continued

access to capital and financial resources, including our ability to

negotiate financing and lending arrangements on terms that are

acceptable, the outcome of various shareholder litigation recently

filed against us, competitive factors, changes resulting from the

recently enacted healthcare reform in the U.S., including changes in

government reimbursement procedures, dependence upon third-party

vendors, timing of regulatory approvals, and other risks discussed in

the Company's periodic and other filings with the Securities and

Exchange Commission. By making these forward-looking statements, the

Company undertakes no obligation to update these statements for

revisions or changes after the date of this release. There can be no

assurance that the Company will recognize revenue related to its

purchase orders and other commitments in any particular period or at

all because some of these purchase orders and other commitments are

subject to contingencies that are outside of the Company's control. In

addition, these orders and commitments may be revised, modified,

delayed or canceled, either by their express terms, as a result of

negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.

-0- 02/08/2012

/CONTACT: Sam Duggan, Chief Financial Officer, +1-314-678-6007, or Media, Frank Cheng, Senior Vice President, Marketing & Business Development, +1-314-678-6111, both of Stereotaxis, Inc.; or Investors, Gregory Gin, +1-646-445-4801, or Doug Sherk, +1-415-568-4887, both of EVC Group, Inc., for Stereotaxis, Inc.

/Web Site:


CO: Stereotaxis, Inc.

ST: Missouri Canada




-- SF50217 --

0000 02/08/2012 21:05:00 EDT